Novo Nordisk's Buyback Signal Cuts Through the Noise as Investors Weigh a Paediatric Win Against a Cardiology Wound

Novo Nordisk buys back shares despite cardiology trial failures, while semaglutide shows promise in pediatric obesity study.

There is a particular kind of confidence that only shows up in the small print of corporate actions. When Novo Nordisk's board authorised a 15 billion Danish kroner share repurchase tranche back in February, it was a routine capital-return decision. The fact that the company has now ploughed roughly 9 billion of that through the market — buying back more than 32 million B-shares at an average price of 281.63 kroner by 4 September — carries rather more weight given what has happened since.

The timing is the tell. Management has been steadily buying its own equity through a stretch that has seen two Phase 3 cardiology studies pulled, a third already wounded, and the share price drifting well below its January peak. That is not the behaviour of a leadership team rattled by its own pipeline setbacks. It is the behaviour of a management signalling that the balance sheet — and the core business — remains on firmer ground than the headlines suggest.

A Second Casualty in the Cardiology Programme

The latest blow landed on 7 September, when Novo Nordisk pulled the plug on two late-stage trials of Ziltivekimab, its experimental heart drug. The HERMES and ATHENA studies were halted after a data monitoring committee concluded they were unlikely to produce a different outcome from ZEUS, the earlier trial that failed to show the drug meaningfully reduced heart attacks and strokes when that readout disappointed in July.

The two terminated studies had been designed to test the drug in patients with heart failure. Two failed study lines within a year is a pattern, not an outlier — and it underscores just how difficult Novo Nordisk has found it to build a credible pipeline beyond the diabetes and obesity franchise that made its name. One small consolation: the separate ARTEMIS Phase 3 trial, which is examining Ziltivekimab in a post-heart-attack setting, continues as planned with data expected in the first half of 2027.

The Paediatric Counterpoint

The same day brought a reminder of why the core business still commands attention. The STEP-Young study hit its primary endpoint, showing that once-weekly semaglutide delivered a significantly greater BMI reduction than placebo in children aged six to under twelve with obesity after 68 weeks of treatment. By the end of the trial period, 40.4 percent of treated children no longer qualified as obese.

Safety and tolerability were consistent with data from adult and adolescent studies, with no new warning signs around growth or pubertal development. The readout extends the reach of the GLP-1 franchise into a younger patient population and provides additional regulatory ammunition for future label expansions.

That juxtaposition — a paediatric win and a cardiology retreat landing on the same morning — frames the central tension in the Novo Nordisk story. Judged on semaglutide alone, the company is making solid, incremental progress. Judged on its diversification strategy, the picture is one of repeated disappointment.

A Market That Is Not Quite Sure What to Think

The equity is caught between those two narratives. On Tuesday, the shares slipped 2.0 percent, dropping back below their 50-day moving average. The relative strength index sits at 42.7, suggesting consolidation rather than oversold conditions — a market without a clear directional view.

The technical picture in euro terms tells a similar story of drift. The stock trades at around 39.12 euros, roughly 29 percent below its 52-week high of 54.86 euros reached in January. It also sits under its 50-day average of 41.54 euros, a signal that the near-term trend remains pointed down.

Analyst reactions have been mixed and, in some cases, notably cautious. Barclays trimmed its price target from 310 to 300 Danish kroner this morning while holding its "Equal Weight" rating. Analyst James Gordon attributed the adjustment to currency effects within a broader reassessment of the European pharmaceutical sector rather than company-specific concerns — a technical tweak more than a fundamental alarm.

Deutsche Bank has taken a harder line, downgrading the stock to Sell on 27 August and again on 7 September, cutting its price target to 265 Danish kroner. The bank cites softening growth expectations for 2027, the Ziltivekimab setbacks, and a substantial patent-cliff risk later in the decade.

Wegovy's Expanding — But Narrowing — Mandate

With Ziltivekimab's heart-failure ambitions now curtailed, the growth story narrows further onto the semaglutide franchise. The central question for investors is whether the Wegovy family can sustain the growth tempo the market has priced in for the coming years — particularly the oral tablet form, which has secured regulatory approval in the US, UK, EU, UAE and Bahrain, and for which Chinese regulators have accepted an application for review.

Early signals from the tablet's German launch last Friday have been subdued, with the stock giving back around 2.4 percent since. It is an early and imperfect indicator, but it hints at how critically the market is scrutinising every new avenue of growth. A successful China approval would open a vast market for oral obesity therapies — a segment where Novo Nordisk already positions itself as a pioneer. A protracted or underwhelming process would leave the company without a credible second growth leg alongside its existing GLP-1 operations.

The September Reckoning

The next test comes on 21 September, when management hosts its capital markets day in London. Investors will be looking for a credible answer on how the company intends to fill the Ziltivekimab-shaped hole in its pipeline, and whether the buyback programme — still running with roughly 6 billion kroner of headroom until early February 2027 — signals anything about management's own view of the equity's value.

The nine-month results due on 4 November will provide the next concrete checkpoint after that. Between now and then, the bull case rests on the paediatric data, the ongoing buyback, and the possibility that management delivers a convincing strategic response in London. The bear case rests on a thinning pipeline, Deutsche Bank's scepticism, and the risk that the China timeline slips.

For now, Novo Nordisk remains a stock caught between two stories: a diversification strategy that has yet to deliver, and a core franchise that continues to perform. Buying back your own shares at a time like this is one way of saying which of those stories you believe.